Clinical Trial Update: Study of ARC-520 in Patient With Chronic Hepatitis B Virus [Phase 2]

View source ↗

Summary

A Phase 2 study of ARC-520 for chronic hepatitis B has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-520

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Chronic Hepatitis B | Phase 2 | Status: WITHDRAWN